This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Investigators from the California Department of Public Health (CDPH), Richmond, CA, and the University of California, Berkeley, CA, conducted a retrospective study to assess the efficacy of Human Botulism Immune Globulin (BIG-IV) in treating infant botulism. CDPH developed BIG-IV, which was licensed in 2003, and CDPH is the sole source of BIG-IV in the United States. For the study, the investigators reviewed the medical records of all patients with laboratory-confirmed infant botulism in the United States treated with BIG-IV from 2003 to 2015. The primary outcomes were length of stay (LOS) and hospital charges. Outcomes in children treated with BIG-IV were compared to those of patients receiving placebo in the BIG-IV Pivotal Trial, conducted from …
Individual Login
Institutional Login
You may be able to gain access using your login credentials for your institution. Contact your librarian or administrator if you do not have a username and password.
Log in through your institution
Purchase access
In this issue
Jump to section
Related Articles
Cited By...
- No citing articles found.